Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 16 de 16
Filter
1.
Animal ; 18(4): 101117, 2024 Apr.
Article in English | MEDLINE | ID: mdl-38520773

ABSTRACT

Environmental conditions and available forage on pastures greatly differ between different farming systems, which can affect the behaviour of grazing cattle. The interplay between environment-, forage-, and animal-related variables may affect the use of feed and water resources in grazing-based systems. Hence, our objectives were (i) to study the differences between grazing-based systems and seasons in environment- and pasture-related variables as well as the behaviour, feed intake, performance, and water productivity of Nellore heifers, and (ii) to understand the interrelationships between these variables. The measurements were performed in a conventional grazing system (CON), an integrated crop-livestock (ICL), and a crop-livestock-forestry (ICLF) systems in the Brazilian Cerrado during the rainy and dry seasons. Ambient temperature and relative air humidity were hourly measured in both seasons. Forage biomass and sward height were determined every month. Forage samples were taken to determine the proportions of alive leaves, alive stems, and dead plant material and to analyse their nutritive value. Forage intake, drinking water intake, and liveweight changes were quantified in 12 Nellore heifers per system and season. Feeding behaviour was recorded by chewing sensors on nine continuous days in each season. Drinking water intake was measured by water meters attached to drinking water troughs, whereby trial cameras at the troughs recorded the frequency of drinking events of individual animals. Feed conversion efficiency and water productivity were estimated. The ICLF reduced the exposure time to high ambient temperatures so that heifers even grazed during the hottest hours. Forage biomass in ICL and CON had greater proportions of stem and dead plant material than in ICLF. Forage intake rate was greater and grazing events were longer for animals in ICLF than those in CON, whereas the daily number of grazing events was greater in CON. Feed conversion efficiency and water productivity were greater in integrated systems than in CON. Amongst studied variables, thermal environment and forage canopy structure with its proportions of dead plant material are the main driving factors for animal behaviour, forage intake rate, and animal performance. These variables reduce feed conversion efficiency and water productivity in grazing cattle. Further research should analyse strategies for promoting thermal comfort for the animals, increasing the proportions of alive biomass, and enhancing the nutritional value of pastures for more efficient use of forage and water resources in grazing-based systems.


Subject(s)
Diet , Drinking Water , Animals , Cattle , Female , Animal Feed/analysis , Diet/veterinary , Drinking Water/analysis , Eating , Feeding Behavior , Livestock , Poaceae , Seasons , Brazil
3.
Anim Reprod Sci ; 117(3-4): 295-301, 2010 Feb.
Article in English | MEDLINE | ID: mdl-19556081

ABSTRACT

In vitro penetration (IVP) of swine oocytes by homologous spermatozoa was evaluated in two experiments using four boars as semen donors. In experiment 1, the IVP rate and the number of penetrating spermatozoa (PSP) were compared using three co-incubation systems for vitrified oocytes and fresh sperm: (1) 35mL petri dishes in a CO(2) incubator, (2) 35mL petri dishes in bags (submarine system) and (3) glass flasks partially submerged in water bath with the same gas mixture used for the bag system. Mean PSP was 8.2+/-10.1 and the IVP rate was 90.5%. The PSP differed across all systems (P=0.0006): 15.5+/-0.5 for flasks, 6.3+/-0.4 for CO(2), and 3.9+/-0.4 for bags. The IVP rate for flasks (95.0%) was greater (P=0.01) than for CO(2) and bags (90.8% and 85.0%, respectively), but it did not differ between flasks and CO(2) for three boars (P>0.05). In experiment 2, co-incubation was done as described for glass flasks in experiment 1. The IVP rate and PSP were compared for cryopreserved oocytes: either vitrified in open pulled straws (OPS), or frozen in cryotubes. Mean PSP was 5.4+/-6.5 and IVP rate was 89.6%. Both PSP and IVP rate were greater (P<0.0001) for oocytes frozen in cryotubes (7.0+/-0.3% and 95.8%, respectively) than those frozen in OPS (3.7+/-0.3% and 83.4%, respectively), with no differences found for three boars (P>0.05). In summary, successful IVP of swine oocytes by homologous spermatozoa can be achieved using gametes incubated in glass flasks and oocytes frozen in cryotubes.


Subject(s)
Cryopreservation/methods , Fertilization in Vitro/methods , Oocytes , Sperm-Ovum Interactions/physiology , Swine , Animals , Cells, Cultured , Coculture Techniques/methods , Culture Media/pharmacology , Embryo Culture Techniques , Female , Fertilization in Vitro/veterinary , Germ Cells/cytology , Germ Cells/physiology , Male , Swine/physiology
4.
Braz. j. med. biol. res ; 39(10): 1315-1322, Oct. 2006. ilus, tab
Article in English | LILACS | ID: lil-437809

ABSTRACT

Patients with diffuse large B-cell lymphoma treated in a University Hospital were studied from 1990 to 2001. Two treatment regimens were used: ProMACE-CytaBOM and then, from November 1996 on, the CHOP regimen. Complete remission (CR), disease-free survival (DFS), and overall survival (OS) rates were determined. Primary refractory patients and relapsed patients were also assessed. A total of 111 patients under 60 years of age were assessed and ranked according to the international prognostic index adjusted to age. Twenty (18 percent) of them were classified as low risk, 40 (36 percent) as intermediate risk, 33 (29.7 percent) as high intermediate risk, and 18 (16.3 percent) as high risk. Over a five-year period, OS and DFS rates were 71 and 59 percent, respectively, for all patients. For the same time period, OS and DFS rates were 72.8 and 61.3 percent, respectively, for 77 patients treated with CHOP chemotherapy and 71.3 and 60 percent for patients treated with the ProMACE-CytaBOM protocol. There was no significant difference in OS or DFS between the two groups. Eleven of 50 refractory and relapsed patients were consolidated with high doses of chemotherapy. Three received allogenic and 8 autologous bone marrow transplantation. For the latter, CR was 62.5 percent and mean OS was 41.1 months. The clinical behavior, CR, DFS, and OS of the present patients were similar to those reported in the literature. We conclude that both the CHOP and ProMACE-CytaBOM protocols can be used to treat diffuse large B-cell lymphoma patients, although the CHOP protocol is preferable because of its lower cost and lower toxicity.


Subject(s)
Humans , Male , Female , Adult , Antineoplastic Combined Chemotherapy Protocols , Lymphoma, Large B-Cell, Diffuse , Disease-Free Survival , Neoplasm Staging , Remission Induction , Survival Analysis , Treatment Outcome
5.
Braz J Med Biol Res ; 39(10): 1315-22, 2006 Oct.
Article in English | MEDLINE | ID: mdl-16906323

ABSTRACT

Patients with diffuse large B-cell lymphoma treated in a University Hospital were studied from 1990 to 2001. Two treatment regimens were used: ProMACE-CytaBOM and then, from November 1996 on, the CHOP regimen. Complete remission (CR), disease-free survival (DFS), and overall survival (OS) rates were determined. Primary refractory patients and relapsed patients were also assessed. A total of 111 patients under 60 years of age were assessed and ranked according to the international prognostic index adjusted to age. Twenty (18%) of them were classified as low risk, 40 (36%) as intermediate risk, 33 (29.7%) as high intermediate risk, and 18 (16.3%) as high risk. Over a five-year period, OS and DFS rates were 71 and 59%, respectively, for all patients. For the same time period, OS and DFS rates were 72.8 and 61.3%, respectively, for 77 patients treated with CHOP chemotherapy and 71.3 and 60% for patients treated with the ProMACE-CytaBOM protocol. There was no significant difference in OS or DFS between the two groups. Eleven of 50 refractory and relapsed patients were consolidated with high doses of chemotherapy. Three received allogenic and 8 autologous bone marrow transplantation. For the latter, CR was 62.5% and mean OS was 41.1 months. The clinical behavior, CR, DFS, and OS of the present patients were similar to those reported in the literature. We conclude that both the CHOP and ProMACE-CytaBOM protocols can be used to treat diffuse large B-cell lymphoma patients, although the CHOP protocol is preferable because of its lower cost and lower toxicity.


Subject(s)
Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Lymphoma, B-Cell/drug therapy , Lymphoma, Large B-Cell, Diffuse/drug therapy , Adult , Antineoplastic Combined Chemotherapy Protocols/administration & dosage , Bleomycin/administration & dosage , Cyclophosphamide/administration & dosage , Cytarabine/administration & dosage , Disease-Free Survival , Doxorubicin/administration & dosage , Etoposide/administration & dosage , Female , Humans , Male , Methotrexate/administration & dosage , Neoplasm Staging , Prednisone/administration & dosage , Remission Induction , Survival Analysis , Treatment Outcome , Vincristine/administration & dosage
6.
Bone Marrow Transplant ; 33(1): 9-13, 2004 Jan.
Article in English | MEDLINE | ID: mdl-14578930

ABSTRACT

Busulfan was added at the dose of 4 mg/kg to 200 mg/kg cyclophosphamide in 81 patients (3-53 years, median 24) with aplastic anemia to reduce graft rejection. Graft-versus-host disease (GVHD) prophylaxis comprised cyclosporine-methotrexate. The number of prior transfusions was 0-276 (median 26), and 48% had received prior immunosuppressive therapy. Two patients experienced primary graft failure, and 10 secondary rejection at 28-1001 days (median 317 days). The cumulative incidence of rejection was 22%; for heavily transfused patients (>/=50 U) it was 43% compared to 16% for the rest (P=0.06). Overall survival rate at 8 years was 56%; patients who received 15 transfusions was 78 and 50%, respectively (P=0.01), whereas it was 67 and 28% for 50 transfusions, respectively (P=0.002). In multivariate analysis, higher number of prior transfusions, shorter period of immunosuppression with cyclosporine and GVHD were associated with inferior survival; moreover, a higher risk of graft rejection were associated with a higher number of prior transfusions and a trend was observed for a shorter cyclosporine administration. Low-dose busulfan is feasible and may be helpful in patients exposed to <50 transfusions. However, rejection remains a significant problem, mainly in heavily transfused patients.


Subject(s)
Anemia, Aplastic/therapy , Bone Marrow Transplantation/methods , Busulfan/administration & dosage , Cyclophosphamide/administration & dosage , Graft Rejection/prevention & control , Transplantation Conditioning/methods , Adolescent , Adult , Anemia, Aplastic/complications , Anemia, Aplastic/mortality , Bone Marrow Transplantation/adverse effects , Cause of Death , Child , Child, Preschool , Drug Therapy, Combination , Graft Survival , Graft vs Host Disease/mortality , Humans , Middle Aged , Survival Analysis , Transplantation Conditioning/mortality , Transplantation, Homologous
7.
Bone Marrow Transplant ; 28(11): 1053-9, 2001 Dec.
Article in English | MEDLINE | ID: mdl-11781616

ABSTRACT

Late CMV disease remains a major concern in allogeneic BMT recipients. Few surveillance data are available on the occurrence of CMV infection and recurrences after day +100. We evaluated the occurrence of antigenemia (AG) recurrences until day +365 in 76 patients who received pre-emptive ganciclovir (GCV) therapy prompted by AG > or = 2 positive cells. Sixty-two episodes of AG recurrences were detected in 33 of the 52 patients who had positive AG. Survival analysis showed a 45.4% probability of AG recurrence on day +100, 64.8% on day +180 and 71.2% on day +365. The median time for AG recurrences was 113 (35 to 343) days. Thirty-five of the 62 episodes (56.4%) occurred after day +100. More than 70% of the patients responded to a 2-week course of GCV and no CMV disease was observed shortly after discontinuation of GCV. The Cox proportional model showed a significant effect of AG recurrences on patient's follow-up only when the patient developed chronic GVHD (P = 0.012). Extended surveillance favored early introduction of GCV and late CMV pneumonia occurred in only one of the 76 patients (1.3%). AG recurrences are frequent after day +100 and extended surveillance until day +365 is recommended for patients who develop chronic GvHD.


Subject(s)
Antigens, Viral/blood , Bone Marrow Transplantation/adverse effects , Bone Marrow Transplantation/immunology , Cytomegalovirus Infections/diagnosis , Cytomegalovirus Infections/immunology , Acute Disease , Adolescent , Adult , Child, Preschool , Chronic Disease , Cytomegalovirus/drug effects , Cytomegalovirus/immunology , Cytomegalovirus/isolation & purification , Cytomegalovirus Infections/mortality , Cytomegalovirus Infections/prevention & control , Follow-Up Studies , Ganciclovir/therapeutic use , Humans , Middle Aged , Secondary Prevention , Survival Rate , Transplantation, Homologous
8.
Bone Marrow Transplant ; 26(4): 413-7, 2000 Aug.
Article in English | MEDLINE | ID: mdl-10982288

ABSTRACT

The incidence, treatment and outcome of CMV interstitial pneumonia (CMV-IP) were reviewed in 139 consecutive allogeneic BMT patients undergoing extended CMV antigenemia surveillance and two different ganciclovir (GCV) strategies to control CMV infection. Nineteen cases of CMV-IP were reviewed, 16 of 63 patients (25.4%) who received early GCV treatment (ET) and three of 76 patients (3.9%) who received preemptive (PE) GCV therapy. In the ET group, the median time for occurrence of CMV-IP was 55 (range 36 to 311) days. Two patients had three episodes of CMV-IP recurrences after day +100. CMV-IP-related death occurred in two patients (15.4%). In the PE group, 41 patients received pre-emptive GCV therapy prompted by the appearance of positive antigenemia > or =2 cells. The median time for the occurrence of CMV-IP was 92 (range 48 to 197) days. Response to therapy was observed when GCV was introduced within 6 days of antigenemia positivity. The use of IVIg in association with GCV did not play a major role in response to therapy. The median time for occurrence of CMV-IP was delayed during PE strategy and the cost-effectiveness of CMV surveillance after day +100 should be investigated in this population.


Subject(s)
Bone Marrow Transplantation/adverse effects , Cytomegalovirus Infections/drug therapy , Ganciclovir/administration & dosage , Pneumonia, Viral/drug therapy , Adolescent , Adult , Antigens, Viral/metabolism , Antiviral Agents/administration & dosage , Antiviral Agents/standards , Child , Child, Preschool , Cytomegalovirus Infections/epidemiology , Cytomegalovirus Infections/immunology , Drug Therapy, Combination , Ganciclovir/standards , Humans , Immunoglobulins, Intravenous/administration & dosage , Immunoglobulins, Intravenous/standards , Incidence , Lung Diseases, Interstitial/drug therapy , Lung Diseases, Interstitial/epidemiology , Lung Diseases, Interstitial/virology , Middle Aged , Pneumonia, Viral/epidemiology , Premedication , Retrospective Studies , Survival Rate , Transplantation, Homologous/adverse effects , Treatment Outcome
10.
Rev Inst Med Trop Sao Paulo ; 40(5): 321-3, 1998.
Article in English | MEDLINE | ID: mdl-10030078

ABSTRACT

A forty-year-old man underwent an allogeneic BMT from his HLA identical sister. GvHD prophylaxis was done with cyclosporine (CyA), methotrexate and prednisone (PDN). On day +90 extensive GvHD was noted and higher doses of immunosuppressive drugs alternating CyA with PDN were initiated. Patient's follow-up was complicated by intermittent episodes of leukopenia and monthly episodes of sinusitis or pneumonia. One year after BMT, the patient developed hoarseness and nasal voice. No etiologic agent could be identified on a biopsy sample of the vocal chord. Upon tapering the doses of immunosuppressive drugs, the patient had worsening of chronic GvHD and was reintroduced on high doses of cyclosporine alternating with prednisone on day +550. Three months later, GvHD remained out of control and the patient was started on azathioprine. On day +700, hoarseness and nasal voice recurred. Another biopsy of the left vocal chord failed to demonstrate infection. Episodes of sinusitis became more frequent and azathioprine was withheld 3 months after it was started. One month later, the patient had bloody nasal discharge and surgical drainage of maxillary sinuses was performed. Histopathology showed hyphae and cultures grew Scedosporium apiospermum. Itraconazole 800 mg/day was initiated. The patient developed progressive respiratory failure and died 15 days later.


Subject(s)
Bone Marrow Transplantation , Dermatomycoses/diagnosis , Pseudallescheria , Sinusitis/microbiology , Adult , Fatal Outcome , Graft vs Host Disease/complications , Humans , Male , Postoperative Complications
11.
Rev. Assoc. Med. Bras. (1992, Impr.) ; 43(2): 93-8, abr.-jun. 1997. tab, graf
Article in Portuguese | LILACS | ID: lil-197139

ABSTRACT

A infusao de células hematopoéticas totipotentes criopreservadas permite a recuperaçao da hematopoese após quimioterapia mieolblativa. Objetivo. A formaçao de cristais de gelo durante o processo de congelamento é o fator principal que causa ruptura das estruturas celulares. A criopreservaçao dessas células a uma taxa constante preveniria os danos causados pelo congelamento brusco. Métodos. Vinte e três pacientes com mediana de 25 anos (variaçao 3-57) tiveram a medula óssea e/ou células-tronco periféricas (CTP) coletadas no período de março de 1993 a outubro de 1994, totalizando 86 congelamentos. Os pacientes apresentavam as seguintes neoplasias: linfoma nao-Hodgkin (n=5), leucemia mielóide aguda (n=8), leucemia linfóide aguda (n=6), doença de Hodkin (n=3) e mieloma múltiplo (n=1). O congelamento foicontrolado por um computador, acoplado ao sistema, às seguintes temperaturas: -1 graus Celsius/min até -45 graus Celsius e depois a -10 graus Celsius/min até -80 graus Celsius. Após o congelamento, as células foram mantidas em freezer a -110 graus Celsius até o momento da infusao. Para obtençao das CTP, empregou-se o fator de crescimento estimulante de granulócitos (G-CSF). Resultados. Uma mediana de 3,16 x 10(8) céls./kg (variaçao 0,86-24,22) de CTP e 2,03 x 10(8) céls./kg (variaçao 0,19-12,21) de medula óssea foi congelada. A mediana para atingir granulócitos maior ou igual a 500/muL e plaquetas maior que 20.000/muL foi de 12 dias (variaçao 8-40) e 31 dias (variaçao 8-80), respectivamente. Todos os pacientes tiveram recuperaçao hematopoética após a infusao das células criopreservadas. Conclusao. A criopreservaçao em congelador program vel permite o armazenamento de células hematopoéticas e, potencialmente, pode causar menor dano celular.


Subject(s)
Female , Humans , Child, Preschool , Middle Aged , Adult , Adolescent , Child , Stem Cells , Bone Marrow , Cryopreservation/methods , Transplantation, Autologous/methods , Freezing , Hematopoiesis , Neoplasms/drug therapy , Antineoplastic Agents/therapeutic use
12.
Rev Assoc Med Bras (1992) ; 43(2): 93-8, 1997.
Article in Portuguese | MEDLINE | ID: mdl-9336042

ABSTRACT

UNLABELLED: The cryopreservation of hematopoietic stem cells can be used for rescuing the hematopoiesis after high dose chemotherapy. PURPOSE: The ice crystal formation during the freezing procedure is the key point that can be harmful to the cells. The cryopreservation of hematopoietic stem cells in a controlled-rate freezer could decrease the cell damage. METHODS: Twenty-three patients with a median age of 26 years (range 03-57) had bone marrow and/or peripheral blood stem cells harvested from March 1993 through October 1994, ending up to 86 freezing procedures. The patient's diagnoses are as follows: Non-Hodgkin's Lymphoma (n = 5); Acute Myelogenous Leukemia (n = 8); Acute Lymphocytic Leukemia (n = 6); Hodgkin's disease (n = 3); Multiple Myeloma (n = 1). The cells were frozen away in a controlled-rate freezer chamber at the following rate: -1 degree C/min from room temperature to -45 degrees C and then, at -10 degrees C/min down to -80 degrees C. After freezing, the cells were kept into mechanical freezers until the marrow infusion. To mobilize PBSC (peripheral blood stem cells), G-CSF (granulocyte colony stimulating factor) was given. RESULTS: A median of 3.16 x 10(8) cells/kg (range 0.86-24.22) of PBSC and 2.03 x 10(8) cells/kg (0.19-12.21) of bone marrow cells were frozen. The median time to reach granulocytes greater than 500/microL and platelets greater than 20,000/microL was 12 days (range 8-40) and 31 days (range 8-80), respectively. All patients had marrow engraftment after infusion of hematopoietic stem cells. CONCLUSION: The cryopreservation procedure using a controlled-rate freezer can store hematopoietic stem cells and potentially, cause less damage to the cells.


Subject(s)
Bone Marrow , Cryopreservation/methods , Stem Cells , Adolescent , Adult , Child , Child, Preschool , Female , Hematopoiesis , Humans , Male , Middle Aged
13.
Bone Marrow Transplant ; 19(3): 299-300, 1997 Feb.
Article in English | MEDLINE | ID: mdl-9028563

ABSTRACT

The Brazilian unrelated bone marrow donor program began in 1993 and an unrelated matched donor was found for a Fanconi anemia patient without a sibling match. An 11-year-old female recipient received FTBI (6.0 Gy) and cyclophosphamide (40 mg/kg) as conditioning. The 41-year-old female unrelated donor received G-CSF at 5 micrograms/kg x 5 days, and on day 6 and 7 postmobilization, peripheral blood stem cells were harvested. Engraftment was seen on day 19 post-BMT and she remains alive and well on day 191+. This case supports the potential role of harvesting G-CSF-stimulated PBSC for unrelated bone marrow transplantation.


Subject(s)
Fanconi Anemia/therapy , Hematopoietic Stem Cell Transplantation , Child , Female , Histocompatibility Testing , Humans , Transplantation, Homologous
14.
Bone Marrow Transplant ; 19(1): 81-2, 1997 Jan.
Article in English | MEDLINE | ID: mdl-9012936

ABSTRACT

Nocardiosis has rarely been described after BMT. When the doses of immunosuppressive therapy were tapered, a 46-year-old BMT recipient developed chronic graft-versus-host disease (GVHD) and immunosuppresive drugs were increased. Sixteen days later the patient developed nocardiosis diagnosed by lung biopsy. Trimethoprim/sulfamethoxazole (TMP/SMZ) was initiated but the doses were reduced because of rising creatinine levels. Skin and cerebral dissemination of nocardiosis was observed and TMP/SMZ doses were increased. After 4 months, the brain lesion was unaltered despite resolution of pulmonary lesions. Clinical improvement was observed after drainage of the brain abscess.


Subject(s)
Bone Marrow Transplantation/adverse effects , Graft vs Host Disease/etiology , Immunosuppressive Agents/therapeutic use , Nocardia Infections/etiology , Nocardia/isolation & purification , Anti-Bacterial Agents/therapeutic use , Anti-Infective Agents, Urinary/therapeutic use , Graft vs Host Disease/drug therapy , Humans , Male , Middle Aged , Nocardia Infections/drug therapy , Nocardia Infections/physiopathology , Sulfamethoxazole/therapeutic use , Trimethoprim/therapeutic use
16.
Medicina (Ribeiräo Preto) ; 16(3/4): 53-60, 1983.
Article in Portuguese | LILACS | ID: lil-18729

ABSTRACT

Os autores estudam a existencia de exames sorologicos multiplos, e seus resultados, em uma amostra casual simples de prontuarios medicos de pacientes de 3 grandes clinicas de um hospital universitario.Mais da metade dos prontuarios amostrados tinha ao menos um exame de perfil 1 e 2 realizado. O numero de resultados normais foi grande. Mais ou menos 30% dos exames tinham apenas 1 resultado alterado e 23% tinham 2 ou 3 exames anormais. Os resultados sugerem que as baterias de exames realizados nao tinham por objetivo elucidar hipoteses diagnosticas dos pacientes; por outro lado, se a utilizacao dirigia-se ao controle de saude e diagnostico precoce de doencas em populacao usuaria de servico terciario, a proporcao dos achados foi muito baixa. As queixas dos pacientes, referidas no prontuario, nao justificam, na maioria dos casos, os exames realizados. E preciso desenvolver o pensamento critico a respeito da utilizacao de recursos tecnologicos a fim de propiciar seu uso mais criterioso


Subject(s)
Humans , Clinical Laboratory Techniques , Hospitals, University
SELECTION OF CITATIONS
SEARCH DETAIL
...